{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:11:35Z","timestamp":1778213495048,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:13:17Z","timestamp":1748070797000},"page":"521.e1-521.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate"],"prefix":"10.1016","volume":"43","author":[{"given":"Alexander C.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"McElree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen Y.","family":"Hougen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2025.04.007_bib0002","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.007_bib0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/BLC-200404","article-title":"Revisiting an old conundrum: a systematic review and meta-analysis of intravesical therapy for treatment of urothelial carcinoma of the prostate","volume":"7","author":"Kokorovic","year":"2021","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.007_bib0004","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0090-4295(89)90314-2","article-title":"Conservative treatment of superficial transitional cell carcinoma of prostatic urethra with intravesical BCG","volume":"34","author":"Orihuela","year":"1989","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.007_bib0005","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-5347(17)41031-7","article-title":"Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra","volume":"141","author":"Bretton","year":"1989","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.007_bib0006","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, Gemcitabine and Cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.007_bib0007","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MOU.0000000000000863","article-title":"The current landscape of salvage therapies for patients with bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer","volume":"31","author":"Packiam","year":"2021","journal-title":"Curr Opin Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.04.007_bib0008","doi-asserted-by":"crossref","first-page":"491.e1","DOI":"10.1016\/j.urolonc.2022.06.007","article-title":"A longitudinal single center analysis of T1HG bladder cancer: an 18 year experience","volume":"40","author":"Yong","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.04.007_bib0009","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.04.007_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/JU.0000000000002848","article-title":"Sequential intravesical valrubicin and docetaxel for the salvage treatment of non-muscle-invasive bladder cancer","volume":"208","author":"McElree","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.04.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.urolonc.2025.04.007_bib0012","first-page":"2561","article-title":"PD26-07\u2003Sequential endoluminal cabazitaxel and gemcitabine with Pembrolizumab for docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts","volume":"16","author":"Packiam","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.007_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.04.007_bib0014","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.007_bib0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.juro.2013.07.062","article-title":"Muscle invasive bladder cancer: examining survivor burden and unmet needs","volume":"191","author":"Mohamed","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.04.007_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2003.12.014","article-title":"Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder","volume":"45","author":"Canda","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.04.007_bib0017","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3816\/CGC.2007.n.021","article-title":"Long-term follow-up of intravesical bacillus Calmette-Gu\u00e9rin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra","volume":"5","author":"Taylor","year":"2007","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2025.04.007_bib0018","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1464-410X.2008.08210.x","article-title":"Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Gu\u00e9rin immunotherapy?","volume":"103","author":"Gofrit","year":"2009","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.04.007_bib0019","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2025.04.007_bib0020","doi-asserted-by":"crossref","first-page":"e15639","DOI":"10.1200\/jco.2015.33.15_suppl.e15639","article-title":"Urothelial carcinoma of the prostatic urethra: long-term follow-up study","volume":"33","author":"Celestino","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:47:11Z","timestamp":1778212031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001516"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}